-transparent.png){kind=logo}
The localization of bombesin gene products in neuroendocrine tumors was achieved by a number of techniques used in combination. These included immunocytochemistry, radioimmunoassay, and chromatographic procedures using a variety of region-specific antibodies recognizing separate portions of probombesin. In situ hybridization using cRNA probes was employed to analyze bombesin gene expression at a cellular level. A novel procedure using a divalent form of bombesin and gold-labeled monoclonal antibodies for the localization of bombesin binding sites at the ultrastructural level was employed in this study. Antibodies to neuron-specific enolase and electron microscopy were employed for the determination of neuroendocrine differentiation. Surgical samples of pulmonary (n = 250) and nonpulmonary (n = 28) small cell carcinomas, 49 carcinoids, and 62 atypical lung carcinoids were investigated and compared with 169 control tumors, including lymphomas, adenocarcinomas, squamous cell carcinomas, and non-small-cell undifferentiated tumors. Cell lines cultured from pulmonary small cell carcinoma and smear preparations of pleural effusions from patients with small cell carcinoma of the lung were also investigated. Strong immunostaining for neuron-specific enolase was noted in all neuroendocrine tumors investigated, and no immunoreactivity was noted in control cases. Electron-dense neurosecretory granules were abundant in carcinoid tumors, scattered in small cell carcinoids, and absent in control cases. Immunostaining for bombesin was particularly strong in benign carcinoids, whereas the more malignant neuroendocrine tumors (e.g., small cell carcinomas) stained best with antibodies to the carboxyl-terminal flanking portion of human probombesin (proGRP). These findings were further validated by radioimmunoassay and chromatography of tissue extracts. Specific binding sites for bombesin were demonstrated on the surface of small cell carcinoma cells maintained in culture. In situ hybridization demonstrated mRNA for preprobombesin in all small cell carcinomas investigated, including surgical samples, cytological preparations, and cell lines. Hybridization reactions varied in intensity, with some cells in autoradiograms almost masked by silver grains and others showing much lighter deposits.
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
December 1978,
General and comparative endocrinology,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
January 1988,
Annals of the New York Academy of Sciences,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
August 1979,
Federation proceedings,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
June 1995,
Appetite,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
July 1996,
Critical reviews in oncology/hematology,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
June 1985,
The Journal of clinical endocrinology and metabolism,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
October 1975,
British journal of pharmacology,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
January 1981,
Peptides,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
November 1981,
Life sciences,
J M Polak, and
Q Hamid, and
D R Springall, and
F Cuttitta, and
E Spindel, and
M A Ghatei, and
S R Bloom
May 1980,
Life sciences,
